Technical Analysis for ALXO - ALX Oncology Holdings Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | N/A | Down | Down |
Historical ALXO trend table... |
Date | Alert Name | Type | % Chg |
---|---|---|---|
MACD Bearish Signal Line Cross | Bearish | 0.66% | |
Multiple of Ten Bearish | Other | 0.66% | |
Wide Bands | Range Expansion | 0.66% | |
Below Lower BB | Weakness | 0.66% | |
Lower Bollinger Band Touch | Weakness | 0.66% | |
Fell Below 20 DMA | Bearish | -8.53% | |
180 Bearish Setup | Bearish Swing Setup | -8.53% | |
Multiple of Ten Bearish | Other | -8.53% | |
Wide Bands | Range Expansion | -8.53% | |
Crossed Above 20 DMA | Bullish | -19.19% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time |
---|---|
Down 3% | about 2 hours ago |
60 Minute Opening Range Breakdown | about 3 hours ago |
Down 2 % | about 3 hours ago |
Down 1% | about 5 hours ago |
Fell Below Previous Day's Low | about 5 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: ???
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic used for the treatment of myelodysplastic syndromes and acute myeloid leukemia, as well as a range of solid tumor indications, including head and neck squamous cell and human epidermal growth factor receptor 2 positive gastric/gastroesophageal junction carcinoma. The company was founded in 2015 and is based in Burlingame, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Oncology Cancer Immunotherapy Acute Myeloid Leukemia Carcinoma Myelodysplastic Syndrome Epidermal Growth Factor Receptor Syndromes Solid Tumor Myelodysplastic Syndromes CD47 Treatment Of Myelodysplastic Syndrome
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Oncology Cancer Immunotherapy Acute Myeloid Leukemia Carcinoma Myelodysplastic Syndrome Epidermal Growth Factor Receptor Syndromes Solid Tumor Myelodysplastic Syndromes CD47 Treatment Of Myelodysplastic Syndrome
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 117.45 |
52 Week Low | 28.01 |
Average Volume | 269,674 |
200-Day Moving Average | 0.00 |
50-Day Moving Average | 75.88 |
20-Day Moving Average | 69.94 |
10-Day Moving Average | 69.54 |
Average True Range | 5.76 |
ADX | 16.48 |
+DI | 14.98 |
-DI | 30.37 |
Chandelier Exit (Long, 3 ATRs ) | 65.72 |
Chandelier Exit (Short, 3 ATRs ) | 75.01 |
Upper Bollinger Band | 81.57 |
Lower Bollinger Band | 58.31 |
Percent B (%b) | -0.02 |
BandWidth | 33.26 |
MACD Line | -2.74 |
MACD Signal Line | -2.20 |
MACD Histogram | -0.535 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 67.07 | ||||
Resistance 3 (R3) | 68.01 | 65.92 | 65.55 | ||
Resistance 2 (R2) | 65.92 | 63.59 | 65.45 | 65.04 | |
Resistance 1 (R1) | 61.93 | 62.16 | 60.89 | 60.99 | 64.54 |
Pivot Point | 59.84 | 59.84 | 59.31 | 59.37 | 59.84 |
Support 1 (S1) | 55.85 | 57.51 | 54.81 | 54.91 | 51.36 |
Support 2 (S2) | 53.76 | 56.08 | 53.29 | 50.86 | |
Support 3 (S3) | 49.77 | 53.76 | 50.35 | ||
Support 4 (S4) | 48.83 |